Polovin Andrew sold $221K of TEM

Polovin Andrew (EVP, Chief Legal Officer) sold 2,951 shares of Tempus AI, Inc. (TEM) at $75.00 ($0.22M total) on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Polovin Andrew
Published Sep 19, 2026, 1:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

Form 4 filing provides the first public disclosure of this insider transaction.

02

Market read

The filing is a routine insider sale; traders may note it but it is unlikely to drive significant price movement.

03

What to watch

Potential upcoming legal or regulatory developments not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 18 2026

Background

Tempus AI, Inc. (TEM) is a AI‑driven healthcare data platform listed on NASDAQ.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares for $221,325 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Sale amount is under $250k and represents a small fraction of holdings; impact likely limited.

Market effects

No broader sector impact; insider sale is company‑specific.

Limited to US investors tracking Tempus AI.

Minimal global relevance.

Counterpoint

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

  • Andrew Polovin

    EVP, Chief Legal Officer of Tempus AI.

  • Tempus AI, Inc.

    Provider of AI‑enabled clinical data solutions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.